Structures by: Bonin M.
Total: 34
4-bromo-4'-nitro-biphenyl
C12H8BrNO2
IUCrJ (2016) 3, 3 219-225
a=9.991(3)Å b=14.1075(15)Å c=15.656(4)Å
α=90.00° β=102.00(2)° γ=90.00°
4-bromo-4'-nitro-biphenyl
C12H8BrNO2
IUCrJ (2016) 3, 3 219-225
a=9.971(3)Å b=14.1307(15)Å c=15.650(4)Å
α=90.00° β=101.71(2)° γ=90.00°
4-bromo-4'-cyano-biphenyl
C13H8BrN
IUCrJ (2016) 3, 3 219-225
a=9.6028(9)Å b=14.6523(9)Å c=15.5726(16)Å
α=90.00° β=97.340(8)° γ=90.00°
4-bromo-4'-cyano-biphenyl
C13H8BrN
IUCrJ (2016) 3, 3 219-225
a=9.5964(9)Å b=14.6438(8)Å c=15.5585(15)Å
α=90.00° β=97.429(8)° γ=90.00°
Coanp
C13H19N3O2
RSC Advances (2013) 3, 47 25145
a=26.010(5)Å b=6.6360(13)Å c=7.5136(15)Å
α=90.00° β=90.00° γ=90.00°
Copper(II) bis-benzimidazole oxalate
C16.50H14.88CuN4O5
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=20.046(4)Å b=10.587(2)Å c=17.484(4)Å
α=90.00° β=106.30(3)° γ=90.00°
Manganese(II) bis-benzimidazole oxalate
C48H36Mn3N12O12
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=21.430(4)Å b=12.185(2)Å c=18.746(4)Å
α=90.00° β=95.62(3)° γ=90.00°
Iron(II) bis-benzimidazole oxalate
C48H36Fe3N12O12
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=20.945(2)Å b=12.3461(9)Å c=18.550(2)Å
α=90.00° β=94.530(12)° γ=90.00°
Nickel bis-benzimidazole oxalate
C48H36N12Ni3O12
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=20.4700(19)Å b=12.4768(15)Å c=18.3523(19)Å
α=90.00° β=92.469(5)° γ=90.00°
Copper(II) bis-benzimidazole oxalate
C48H36Cu3N12O12
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=20.657(4)Å b=12.578(3)Å c=18.299(4)Å
α=90.00° β=93.74(3)° γ=90.00°
[Mn(ox)(btz)2]n
C14H10MnN6O4
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=14.551(3)Å b=12.549(3)Å c=9.4577(19)Å
α=90.00° β=109.50(3)° γ=90.00°
Co(ox)(btz)2
C14H10CoN6O4
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=14.436(5)Å b=12.353(3)Å c=9.245(4)Å
α=90.00° β=109.25(3)° γ=90.00°
[Cu(ox)(btz)2]n
C14H10CuN6O4
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=14.2379(2)Å b=12.28010(10)Å c=9.38300(10)Å
α=90.00° β=108.7210(10)° γ=90.00°
Zn(ox)(btz)2
C14H10N6O4Zn
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=14.3720(14)Å b=12.3909(16)Å c=9.2272(9)Å
α=90.00° β=108.751(7)° γ=90.00°
[Zn(bnz)4][Zn2(ox)3]
C28H24N8Zn,2(C3O6Zn)
Dalton transactions (Cambridge, England : 2003) (2010) 39, 20 4937-4950
a=16.642(3)Å b=8.8961(18)Å c=24.002(5)Å
α=90.00° β=90.00° γ=90.00°
C12H8INO2
C12H8INO2
CrystEngComm (2010) 12, 4 1252
a=18.892(6)Å b=8.215(3)Å c=14.400(4)Å
α=90.00° β=90.00° γ=90.00°
C12H8INO2
C12H8INO2
CrystEngComm (2010) 12, 4 1252
a=10.405(3)Å b=14.441(5)Å c=8.194(2)Å
α=90.00° β=112.074(18)° γ=90.00°
Urotropin azelate
(C6H12N4,C9H16O4)
Acta Crystallographica Section B (2003) 59, 1 72-86
a=9.4157(19)Å b=26.124(5)Å c=7.2034(14)Å
α=90.00° β=90.00° γ=90.00°
1:1 adduct of hexamethylenetetramine and azelaic acid
C6H12N4,C9H16O4
Acta Crystallographica Section B (1999) 55, 3 448-458
a=5.8907(7)Å b=26.071(2)Å c=11.8868(11)Å
α=90.00° β=106.118(9)° γ=90.00°
Hexamethylenetetramine-sebacic acid
C10H18O4,C6H12N4
Acta Crystallographica Section C (2001) 57, 8 936-938
a=5.9030(12)Å b=27.549(6)Å c=23.371(5)Å
α=90° β=101.22(3)° γ=90°
PX phase of lead titanate
O3Pb1Ti1
Chemistry of Materials (2011) 23, 10 2529
a=12.3853(1)Å b=12.3853(1)Å c=3.82000(4)Å
α=90° β=90° γ=90°
P1A2/Ru
C88H62N8Ru,4(F6P)
Journal of the American Chemical Society (2002) 124, 1364-1377
a=16.355(3)Å b=16.690(3)Å c=60.729(12)Å
α=90.00° β=90.00° γ=90.00°
H3TP+-tpy
C38H27N4,BF4,0.5(CH3CO2C2H5)
Journal of the American Chemical Society (2002) 124, 1364-1377
a=10.446(2)Å b=13.750(2)Å c=14.169(4)Å
α=116.59(3)° β=105.55(3)° γ=93.46(3)°
P0A/Ru
C53H38N7Ru,(PF6)3,(C2H3N)0.8,(H2O)0.5
Journal of the American Chemical Society (2002) 124, 1364-1377
a=14.366(3)Å b=14.570(3)Å c=14.677(3)Å
α=82.82(3)° β=75.68(3)° γ=82.19(3)°
C35H40Cl3Cu2FN6O16
C35H40Cl3Cu2FN6O16
Inorganic Chemistry (2002) 41, 479-491
a=12.569(6)Å b=18.423(9)Å c=18.919(9)Å
α=90° β=90° γ=90°
C37H42Cl2Cu2N6O12
C37H42Cl2Cu2N6O12
Inorganic Chemistry (2002) 41, 479-491
a=13.278(3)Å b=16.786(3)Å c=17.673(4)Å
α=90° β=91.25(3)° γ=90°
C16.5H21Cl1.5CuF1.5N3O9.5
C16.5H21Cl1.5CuF1.5N3O9.5
Inorganic Chemistry (2002) 41, 479-491
a=16.125(5)Å b=16.553(5)Å c=16.822(4)Å
α=90° β=90° γ=90°
Xaliproden
C23H23ClF3N
Crystal Growth & Design (2013) 13, 11 4678
a=18.4293Å b=7.9248Å c=14.6842Å
α=90° β=103.2813° γ=90°
C32H31Cl2Cu2FN6O10
C32H31Cl2Cu2FN6O10
Inorganic Chemistry (2002) 41, 479-491
a=11.641(4)Å b=22.08(1)Å c=14.161(3)Å
α=90° β=105.00(2)° γ=90°
Pyromorphite
HO13P3Pb5
Crystallography Reports (1998) 43, 189-192
a=9.774Å b=9.774Å c=7.291Å
α=90° β=90° γ=120°
Pizgrischite
Bi17Cu14.77Fe0.23PbS35
The Canadian Mineralogist (2007) 45, 1229-1245
a=35.095Å b=3.9067Å c=43.222Å
α=90° β=96.71° γ=90°
Nabiasite
As0.618BaH2Mn9O26V5.382
European Journal of Mineralogy (1999) 11, 879-890
a=12.832Å b=12.832Å c=12.832Å
α=90° β=90° γ=90°
Cabalzarite
Al0.816As2CaFe0.354H3Mg0.784Mn0.046O10
American Mineralogist (2000) 85, 1307-1314
a=8.925Å b=6.143Å c=7.352Å
α=90° β=115.25° γ=90°
Cabalzarite
Al0.84As2CaFe0.08H3Mg0.82Mn0.26O10
American Mineralogist (2000) 85, 1307-1314
a=8.9284Å b=6.1314Å c=7.3439Å
α=90° β=115.494° γ=90°